Akanda (AKAN) Loans - Gross (2023 - 2025)

Akanda's (AKAN) quarterly Loans - Gross came in at $990688.0 in Q2 2025, up 67.95% year-on-year from $589866.0 in Q2 2024, and up 96.76% quarter-over-quarter from $503493.0 in Q4 2024.

Akanda (AKAN) Loans - Gross (2023 - 2025) Analysis & Trends

Akanda's Loans - Gross history runs 3 years deep, the most recent figure standing at $990688.0 for Q2 2025.

  • On a quarterly basis, Loans - Gross rose 67.95% year-over-year to $990688.0 in Q2 2025; TTM through Jun 2025 was $990688.0, a 67.95% increase from a year earlier, with the FY2024 full-year figure at $503493.0, down 15.13% from the prior year.
  • Loans - Gross advanced to $990688.0 in Q2 2025 per AKAN's latest filing, from $503493.0 in the prior quarter.
  • Across five years, Loans - Gross topped out at $990688.0 in Q2 2025 and bottomed at $503493.0 in Q4 2024.
  • The 3-year median for Loans - Gross is $591549.0 (2023), against an average of $669319.8.
  • Across the five-year window, Loans - Gross declined 15.13% in 2024 and jumped 67.95% in 2025, its largest moves.
  • Year by year, Loans - Gross stood at $593232.0 in 2023, then slipped by 15.13% to $503493.0 in 2024, then jumped by 96.76% to $990688.0 in 2025.
  • Per Business Quant, the three latest AKAN Loans - Gross figures stand at $990688.0 (Q2 2025), $503493.0 (Q4 2024), and $589866.0 (Q2 2024).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Loans - Gross (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn -
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn -
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn -
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -
10 Akanda 556,353.85 556,353.85 - -

Historic Data

Download Data
DateValue
Jun 30, 2025 990,688.00
Dec 31, 2024 503,493.00
Jun 30, 2024 589,866.00
Dec 31, 2023 593,232.00